Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X:
“Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma.
Significant proportion of HCC tumors become ghost tumors (radiologically persistent without viable tumor cells)
Durable: PR/SD >6 mo
IMbrave150
•CR, PR, SD: 8.9%, 22.1%, 44.2%
•77.8% of PRs and 28.5% SDs were durable
•Durable response -> better survival
Real-word, resection after atezo-beva
•pCR: 57.7% of PR tumors, 16.7% of SD tumors”
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Authors: Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Akihiko Soyama, Chang-Tsu Yuan, Tse-Ching Chen, Susumu Eguchi, Tomoharu Yoshizumi, Shinji Itoh, Noriaki Nakamura, Hisashi Kosaka, Masaki Kaibori, Takamichi Ishii, Etsuro Hatano, Chikara Ogawa, Atsushi Naganuma, Satoru Kakizaki, Chih-Hsien Cheng, Po-Ting Lin, Yung-YehSu, Chien-Huai Chuang, Li-Chun Lu, Chi-Jung Wu, Hung-Wei Wang, Kun-Ming Rau, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Sairy Hernandez, Richard S. Finn, Masatoshi Kudo, Ann-Lii Cheng
Source: Erman Akkus/X
For more posts by Erman Akkus, visit oncodaily.com
